GLP-1 receptor agonists reduce body weight by approximately 9% at 3 months, 5% at 6 months, and 4% at 12 months, primarily through fat mass reduction while preserving lean tissue in adults with overweight or obesity.
- GLP-1 medications cause weight loss mainly by reducing fat, not muscle
- Weight reduction averages 9% at 3 months, declining to 4% by 12 months
- Different GLP-1 drugs show varying effectiveness, with liraglutide showing notable variability
How this compares to prior research
Before this meta-analysis, individual studies had shown GLP-1 receptor agonists were effective for weight loss, but comprehensive data on body composition changes and comparisons between different agents were limited. The authors note that understanding whether weight loss comes from fat or muscle is critical for assessing treatment quality. This systematic review of 36 studies provides the first comprehensive synthesis of how these medications affect both total weight and body composition over time.
Obesity prevalence among adults globally, 1990–1999
Key findings
- At 3 months, GLP-1 receptor agonists reduced mean body weight by approximately 9%, with marked reductions in fat mass and visceral adipose tissue
- At 6 months, weight reduction averaged 5% with semaglutide, liraglutide, and exenatide showing comparable effects while lean mass remained largely preserved
- At 12 months, weight loss persisted at around 4% with variability between agents, and fat mass decline predominated while reductions in lean body mass were modest
What this means in practice
- Ask your doctor which specific GLP-1 medication may work best for your individual weight loss goals
- Combine GLP-1 treatment with exercise to maximize lean muscle preservation during weight loss
- Expect the most dramatic weight loss in the first 3 months, with continued but slower reduction over time
Frequently asked questions
Do GLP-1 medications cause muscle loss along with fat loss?
No, GLP-1 receptor agonists primarily reduce fat mass while preserving lean tissue. Reductions in lean body mass were modest across studies, with fat mass decline predominating.
How long does weight loss from GLP-1 medications last?
Weight loss persists at 12 months, though the percentage decreases over time from 9% at 3 months to 4% at 12 months.
Are all GLP-1 medications equally effective for weight loss?
No, there is variability between agents. At 6 months, semaglutide, liraglutide, and exenatide showed comparable effects, but differences emerged at 12 months, most notably with liraglutide.
Key terms explained
GLP-1 receptor agonists
Medications that mimic a natural hormone to regulate blood sugar and appetite, leading to weight loss
Visceral adipose tissue
Deep belly fat surrounding internal organs, associated with higher health risks than subcutaneous fat
Lean body mass
Total body weight minus fat, including muscle, bone, organs, and water
Source: GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. · DOI: doi: 10.1038/s41366-026-02088-1